Real-world effectiveness of dupilumab in patients with asthma: Findings from the US ADVANTAGE study.
Blaiss M, Bleecker ER, Jacob-Nara J, Nair R, Duh MS, Wang Z, Stanford RH, Soler X, Hardin M, Ye M, Khanal A, Borsos K.
Ann Allergy Asthma Immunol. 2024 Apr;132(4):463-468.e1. doi: 10.1016/j.anai.2023.11.006. Epub 2023 Nov 14.
PMID:37967668
MUC1 attenuates neutrophilic airway inflammation in asthma by reducing NLRP3 inflammasome-mediated pyroptosis through the inhibition of the TLR4/MyD88/NF-kappaB pathway.
Liu L, Zhou L, Wang L, Mao Z, Zheng P, Zhang F, Zhang H, Liu H.
Respir Res. 2023 Oct 25;24(1):255. doi: 10.1186/s12931-023-02550-y.
PMID:37880668
Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE study.
Bleecker E, Blaiss M, Jacob-Nara J, Huynh L, Duh MS, Guo T, Ye M, Stanford RH, Wang Z, Soler X, Nag A, Nair R, Borsos K.